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Letters to the Editor
Cardiac Resynchronization
Therapy
Two recent studies published in JACC (1,2) suggest that the
indication for cardiac resynchronization therapy (CRT) may be
extended to heart failure patients with normal QRS width (120
ms) and evidence of mechanical dyssynchrony identified by tissue
Doppler imaging.
Cardiac resynchronization therapy is an electrical therapeutic
approach to treat an electrical conduction delay that in turn causes
mechanical failure, mainly within the left ventricle. This patho-
physiologic concept has been elaborated and proven in numerous
well-designed and well-controlled animal experiments, in hemo-
dynamic studies in humans, and in mathematical models (3–6) but
it is now challenged by a new approach that completely disregards
the traditional electrical basis for resynchronization therapy and
focuses solely on mechanical dyssynchrony.
Although it seems logical to look closer for the presence of
mechanical dyssynchrony, by means of echocardiography or other
imaging modalities, before recommending resynchronization ther-
apy, I believe that we cannot completely ignore the electrocardio-
gram (ECG) at this time. Some important issues have not been
addressed by both studies: how to deliver ventricular pacing in
patients with normal electrical conduction and how to achieve
sufficient ventricular capture to resynchronize ventricular contrac-
tion. It would be interesting to learn more about the intrinsic PR
interval before pacemaker implantation and how the atrioventric-
ular delays were set to ensure ventricular capture without interrup-
tion of atrial filling. How many patients had evidence of complete
ventricular capture by the ECG at rest and in how many patients
was mechanical resynchronization achieved by fusion between
intrinsic activation and the pacing stimuli?
Both trials (1,2) are certainly very intriguing and stimulating,
but they are also clearly limited by their design, mainly due to the
lack of a control group with inactivated pacing. Thus, the 2 studies
can only serve to initiate larger randomized multicenter trials
before the ECG can be completely abandoned as a selection
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Reply
We thank Dr. Breithardt for his interest in our study on cardiac
resynchronization therapy (CRT) in patients with a narrow QRS
complex (120 ms). Our report demonstrates that CRT appears
to be beneficial in 33 patients with narrow QRS complex and
severe left ventricular (LV) dyssynchrony on tissue Doppler imag-
ing, with similar improvement in symptoms and comparable LV
reverse remodeling as in patients with wide QRS complexes (1).
Our results are confirmed by the data of Yu et al. (2) in the same
issue of the Journal and are in line with 2 earlier studies (3,4),
bringing the total of included patients to 118 (2–4). However,
none of the studies to date included a control group of narrow
QRS patients with inactive pacing, which can be considered as a
limitation. We totally agree with Dr. Breithardt that the promising
results of CRT in narrow QRS patients in these initial studies will
now need confirmation in larger multicenter randomized studies
before the current selection criteria can be refined.
A second point raised by Dr. Breithardt is that patients with a
narrow QRS may potentially have a shorter PR interval compared
to patients with a wide QRS, which may lead to a higher number
of patients with fusion of intrinsic activation and the pacing
stimuli. However, a narrow QRS complex in these patients may
not necessarily be associated with a short PR interval. The (degree
of) fusion during CRT is often difficult to assess, and the incidence
of fusion in patients with a wide QRS complex is also unknown.
As indicated, we cannot exclude that some patients may have had
fusion between intrinsic activation and pacing stimuli, but still the
application of CRT resulted in a significant improvement in
clinical and echocardiographic parameters comparable to patients
with a wide QRS complex.
In conclusion, we agree with Dr. Breithardt that there is a clear
need for multicenter randomized trials to confirm the promising
initial results of CRT in heart failure patients with a narrow QRS
complex.
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